EB-BH2026
/ Essen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 01, 2024
BAH246: Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Essen Biotech | Not yet recruiting ➔ Recruiting
CAR T-Cell Therapy • Enrollment open • IO biomarker • Acute Lymphocytic Leukemia • CNS Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • CD5 • CD7
May 20, 2024
BAH246: Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
(clinicaltrials.gov)
- P1/2 | N=60 | Not yet recruiting | Sponsor: Essen Biotech
CAR T-Cell Therapy • IO biomarker • New P1/2 trial • Acute Lymphocytic Leukemia • CNS Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • CD5 • CD7
1 to 2
Of
2
Go to page
1